World's Best Scientists 2026 revealed!

D-Index & Metrics

Economics and Finance

D-Index
33
Citations
5007
World Ranking
3264
National Ranking
375

Best Publications

  • Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

    Courtney Davis;Huseyin Naci;Evrim Gurpinar;Elita Poplavska

  • From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management.

    Elias Mossialos;Emilie Courtin;Huseyin Naci;Shalom Benrimoj

  • Distribution of road traffic deaths by road user group: a global comparison

    H. Naci;Dan Chisholm;Timothy D. Baker

  • Economic burden of multiple sclerosis: a systematic review of the literature.

    Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  • Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

    Huseyin Naci;Jasper J Brugts;Rachael Fleurence;Bernice Tsoi

  • Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

    Huseyin Naci;Huseyin Naci;Courtney Davis;Jelena Savović;Jelena Savović;Julian P T Higgins;Julian P T Higgins;Julian P T Higgins

  • Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

    Huseyin Naci;Katelyn R. Smalley;Aaron S. Kesselheim

  • Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study

    Daniel Chisholm;Huseyin Naci;Adnan Ali Hyder;Nhan T. Tran

  • How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

    Huseyin Naci;John P.A. Ioannidis

  • Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.

    Neville Jackson;Dan Atar;Maria Borentain;Guenter Breithardt

  • Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom.

    Harshil Dhutia;Aneil Malhotra;Vincent Gabus;Ahmed Merghani

  • The Critical Role Of Observational Evidence In Comparative Effectiveness Research

    Rachael L. Fleurence;Huseyin Naci;Jeroen P. Jansen

  • Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

    Maximilian Salcher-Konrad;Huseyin Naci;Courtney Davis

  • Generating comparative evidence on new drugs and devices after approval

    Andrea Cipriani;Andrea Cipriani;John P A Ioannidis;Peter M Rothwell;Paul Glasziou

  • Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

    Rick A Vreman;Huseyin Naci;Huseyin Naci;Wim G Goettsch;Aukje K Mantel-Teeuwisse

  • Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention.

    Tommi Tervonen;Huseyin Naci;Gert van Valkenhoef;Anthony E. Ades

  • The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.

    Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  • Evidence of comparative efficacy should have a formal role in European drug approvals

    Corinna Sorenson;Huseyin Naci;Jonathan Cylus;Elias Mossialos

  • Generating comparative evidence on new drugs and devices before approval

    Huseyin Naci;Maximilian Salcher-Konrad;Aaron Kesselheim;Beate Wieseler

  • Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

    Huseyin Naci;Olivier J. Wouters;Radhika Gupta;John P.A. Ioannidis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: